Potential effects of the new medicare prospective payment system on drug prescription in end-stage renal disease care

Blood Purification

Volumn 31, Issue 1-3, 2011, Pages 66-69

  Winkelmayer, Wolfgang C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost reimbursement; Drug prescription; End stage renal disease; Erythropoiesis stimulating agents; Patient care cost; Patient outcomes

Indexed keywords

ALTEPLASE; ANTIANEMIC AGENT; CALCIMIMETIC AGENT; CALCITRIOL; CARNITINE; CINACALCET; DAPTOMYCIN; DEXTRIFERRON; DOXERCALCIFEROL; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARICALCITOL; RECOMBINANT ERYTHROPOIETIN; VANCOMYCIN; VITAMIN D DERIVATIVE;

ANEMIA; BONE METABOLISM; CAPITATION FEE; CONFERENCE PAPER; DRUG UTILIZATION; HEALTH CARE COST; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; IRON THERAPY; KIDNEY FAILURE; LABORATORY TEST; MEDICAL FEE; MEDICARE; MINERAL METABOLISM; OUTPATIENT CARE; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; REIMBURSEMENT; THROMBOSIS; THROMBOSIS PREVENTION; UNITED STATES; VASCULAR PATENCY; VITAMIN SUPPLEMENTATION;

DRUG PRESCRIPTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICARE; PROSPECTIVE PAYMENT SYSTEM; TERMINAL CARE; UNITED STATES;

EID: 78651426108     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321856     Document Type: Conference Paper

References (4)

1. United States Renal Data System, USRDS 2009 Annual Data Report: Atlas of End- Stage Renal Disease and Chronic Kidney Disease in the United States, Chapter 11: Costs of ESRD. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2009, pp 335-342.
2. Powe NR, Griffiths RI, de Lissovoy G, Anderson GF, Watson AJ, Greer JW, Herbert RJ, Eggers PW, Milam RA, Whelton PK: Access to recombinant erythropoietin by Medicareentitled dialysis patients in the first year after FDA approval. JAMA 1992; 268: 1434-1440.
3. Medicare Program; End-Stage Renal Disease Prospective Payment System. 42 CFR Parts 410, 413 and 414. Fed Regist 2010; 75: 49029-49214.
4. Chertow GM, Winkelmayer WC: On the relative safety of intravenous iron formulations: new answers, new questions. Am J Hematol 2010; 85: 643-644.